{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:10Z","timestamp":1790052970987,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jconrel.2019.09.011","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T11:38:06Z","timestamp":1571225886000},"page":"106-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice"],"prefix":"10.1016","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-6434","authenticated-orcid":false,"given":"Lisa","family":"Munakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Haseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotomo","family":"Machiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Aoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.09.011_bib0005","first-page":"71","article-title":"Harnessing the power of the immune system to target cancer","volume":"Vol 64","author":"Lizee","year":"2013"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of Interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0030","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1021\/acs.molpharmaceut.8b00691","article-title":"TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings","volume":"15","author":"Shetab Boushehri","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14760584.2015.966085","article-title":"Vaccine adjuvant uses of poly-IC and derivatives","volume":"14","author":"Martins","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ctrv.2018.10.012","article-title":"In vivo cancer vaccination: Which dendritic cells to target and how?","volume":"71","author":"Chiang","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0045","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08923973.2013.861481","article-title":"Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis","volume":"36","author":"Qin","year":"2014","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0055","first-page":"640","article-title":"Phase I trials of poly(I,C) complexes in advanced cancer","volume":"4","author":"Krown","year":"1985","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","article-title":"Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists","volume":"61","author":"Vollmer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nm987","article-title":"Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration","volume":"10","author":"Heikenwalder","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0075","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0080","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.4049\/jimmunol.162.4.2368","article-title":"Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis","volume":"162","author":"Sparwasser","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/annonc\/mdr030","article-title":"A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer","volume":"23","author":"Manegold","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0090","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2010.32.8971","article-title":"Randomized phase III trial of paclitaxel\/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer","volume":"29","author":"Hirsh","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0095","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0100","doi-asserted-by":"crossref","first-page":"33071","DOI":"10.1074\/jbc.M311662200","article-title":"Necessity of oligonucleotide aggregation for toll-like receptor 9 activation","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.20140391","article-title":"Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators","volume":"212","author":"Flierl","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0110","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","article-title":"Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide","volume":"2","author":"Henry","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0115","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0006-2952(97)00091-9","article-title":"Effects of synthetic oligonucleotides on human complement and coagulation","volume":"53","author":"Shaw","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0120","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V92.5.1617","article-title":"Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex","volume":"92","author":"Sheehan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0125","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-2669","article-title":"Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models","volume":"77","author":"Bichat","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CJI.0b013e31820d2a05","article-title":"Antitumor activity mediated by CpG: the route of administration is critical","volume":"34","author":"Lou","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0135","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","article-title":"Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs","volume":"166","author":"Verthelyi","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0140","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/316364","article-title":"Development of nonaggregating poly-A tailed immunostimulatory A\/D type CpG oligodeoxynucleotides applicable for clinical use","volume":"2015","author":"Aoshi","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0145","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1074\/jbc.M410868200","article-title":"Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells","volume":"280","author":"Kerkmann","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/ard.1993.3.53","article-title":"Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides","volume":"3","author":"Zhao","year":"1993","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0155","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0160","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","article-title":"Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model","volume":"3","author":"Chen","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0165","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes t cell IFN-\u03b3\u2013Mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/cas.12867","article-title":"Tumor growth suppression by the combination of nanobubbles and ultrasound","volume":"107","author":"Suzuki","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0175","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI44752","article-title":"Paired analysis of TCRalpha and TCRbeta chains at the single-cell level in mice","volume":"121","author":"Dash","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0185","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","article-title":"Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade","volume":"12","author":"Akbay","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0190","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0195","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1248\/bpb.b13-00059","article-title":"The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors","volume":"36","author":"Hatakeyama","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0205","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0210","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0215","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0225","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","article-title":"IL-6 and related cytokines as the critical lynchpins between inflammation and cancer","volume":"26","author":"Taniguchi","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0240","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0245","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0250","first-page":"1165","article-title":"Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice","volume":"118","author":"Liu","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0255","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.immuni.2017.01.003","article-title":"CD8(+) T cells orchestrate pDC-XCR1(+) dendritic cell spatial and functional cooperativity to optimize priming","volume":"46","author":"Brewitz","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0265","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive t cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.09.011_bib0270","first-page":"1193","article-title":"Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy","volume":"53","author":"Wang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0275","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/annonc\/mdy326","article-title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study","volume":"29","author":"Thomas","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0280","doi-asserted-by":"crossref","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","article-title":"Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03077","article-title":"Targeting innate immunity to enhance the efficacy of radiation therapy","volume":"9","author":"Dar","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2019.09.011_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.uct.2007.11.003","article-title":"CpG oligodeoxynucleotides as immunotherapy in cancer","volume":"3","author":"Jahrsdorfer","year":"2008","journal-title":"Update Cancer Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919305528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919305528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:43:48Z","timestamp":1759160628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919305528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":59,"alternative-id":["S0168365919305528"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.09.011","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}